Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia
- 24 May 1990
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (21) , 1494-1499
- https://doi.org/10.1056/nejm199005243222104
Abstract
Familial hypercholesterolemia carries a marked increase in the risk of coronary heart disease (CHD), but there is considerable variation between individuals in susceptibility to CHD. To investigate the possible role of lipoprotein(a) as a risk factor for CHD, we studied the association between serum lipoprotein(a) levels, genetic types of apolipoprotein(a) (which influence lipoprotein(a) levels), and CHD in 115 patients with heterozygous familial hypercholesterolemia. The median lipoprotein(a) level in the 54 patients with CHD was 57 mg per deciliter, which is significantly higher than the corresponding value of 18 mg per deciliter in the 61 patients without CHD. According to discriminant-function analysis, the lipoprotein(a) level was the best discriminator between the two groups (as compared with all other lipid and lipoprotein levels, age, sex, and smoking status). Phenotyping for apolipoprotein(a) was performed in 109 patients. The frequencies of the apolipoprotein(a) phenotypes and alleles differed significantly between the patients with and those without CHD. The allele LpS2, which is associated with high lipoprotein(a) levels, was found more frequently among the patients with CHD (0.33 vs. 0.12). In contrast, the LpS4 allele, which is associated with low lipoprotein(a) levels, was more frequent among those without CHD (0.27 vs. 0.15). We conclude that an elevated level of lipoprotein(a) is a strong risk factor for CHD in patients with familial hypercholesterolemia, and the increase in risk is independent of age, sex, smoking status, and serum levels of total cholesterol, triglyceride, or high-density lipoprotein cholesterol. The higher level of lipoprotein(a) observed in the patients with CHD is the result of genetic influence. (N Engl J Med 1990; 322:1494–9.)This publication has 35 references indexed in Scilit:
- Effect of HELP‐LDL‐apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post‐treatment return to baseline levelsEuropean Journal of Clinical Investigation, 1989
- Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988
- Familial hypercholesterolemia and apolipoprotein E4Atherosclerosis, 1988
- Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitorJournal of Molecular Medicine, 1988
- Teaching old dogmas new tricksNature, 1987
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987
- Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man.Journal of Clinical Investigation, 1983
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a)Atherosclerosis, 1982
- A study of methods of identification and estimation of LP(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosisAtherosclerosis, 1974